Drugs / MART-1 Reactive CD8+ PBL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01495572 | Dec 2011 → Feb 2014 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1 Reactive CD8+ PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01495572 ↗ |
| Modality | Cell therapy | “intravenous adoptive transfer of MART-1:27-35 reactive peripheral blood lymphocytes” NCT01495572 ↗ |
| Route | Intravenous | “Intravenous (IV) over 30 minutes on day 0” NCT01495572 ↗ |